CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2019--
Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology
company developing novel medicines to bring the curative power of stem
cell transplant to more patients, today announced the closing of its
previously announced public offering of 4,887,500 shares of its common
stock, including 637,500 shares of common stock sold pursuant to the
underwriters’ full exercise of their option to purchase additional
shares, at a price to the public of $13.25 per share. The total gross
proceeds from the offering (before deducting underwriters’ discounts and
commissions and estimated offering expenses) are approximately $64.8
million. All shares of common stock were offered by Magenta.
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen acted as joint book
running managers for the offering. Wedbush PacGrow acted as lead manager
for the offering.
A registration statement relating to the offering has been filed with
the United States Securities and Exchange Commission (“SEC”) and became
effective on May 1, 2019. Copies of the prospectus can be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusemail@example.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department,
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any offer or sale of
these securities in any state or other jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a
clinical-stage biotechnology company developing novel medicines for
patients with autoimmune diseases, blood cancers and genetic diseases.
By creating a platform focused on critical areas of unmet need, Magenta
Therapeutics is pioneering an integrated approach to allow more patients
to receive one-time, curative therapies by making the process more
effective, safer and easier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005634/en/
Source: Magenta Therapeutics, Inc.
Manisha Pai, Vice President, Communications &